


Form PTO-1390		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER P26228
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/512090</b>	
INTERNATIONAL APPLICATION NO. PCT/KR03/00921	INTERNATIONAL FILING DATE 09 May 2003	PRIORITY DATE CLAIMED 09 May 2002	
TITLE OF INVENTION SUBSTAINED RELEASE FORMULATION OF PROTEIN AND PREPARATION METHOD THEREOF			
APPLICANT(S) FOR DO/EO/US Hee-Yong LEE, Jung-Soo KIM, Ji-Suk LEE, Jung-In KIM, Yun-Mi SEO, Chae-Jin LIM, Sung-Kyu KIM, Young-Hwan JUNG, Seung-Gu CHANG, and Ho-Il CHOI			
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.</p> <ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below.</li> <li>4. <input type="checkbox"/> The US has been elected (PCT Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).             <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154 (d) (4).</li> </ol> </li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. .371(c)(4)).             <ul style="list-style-type: none"> <li>“Unexecuted”</li> </ul> </li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
Items 11 to 16 below concern other document(s) or information included:			
<ol style="list-style-type: none"> <li>11. Assignee: <u>PEPTRON CO., LTD., of Daejeon, Republic of Korea</u></li> <li>12. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>13. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>14. <input checked="" type="checkbox"/> A FIRST preliminary amendment.             <ul style="list-style-type: none"> <li><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> </ul> </li> <li>15. <input type="checkbox"/> An Application Data Sheet under 37 C.F.R. 1.76.</li> <li>16. <input type="checkbox"/> A substitute specification.</li> <li>17. <input type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>18. <input checked="" type="checkbox"/> Figure of Drawing to be published: <u>14</u></li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154 (d) (4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4).</li> <li>22. <input checked="" type="checkbox"/> Other items or information:             <ul style="list-style-type: none"> <li>Cover Letter Under 35 U.S.C. 371 and 37 C.F.R. 1.495.</li> <li>International Application as published (Cover Sheet).</li> <li>PCT/ISA/210 International Search Report.</li> <li>PCT/IB/308.</li> <li>Claim of Priority.</li> </ul> </li> </ol>			

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/512090</b>		INTERNATIONAL APPLICATION NO. <b>PCT/KR03/00921</b>		ATTORNEY'S DOCKET NUMBER <b>P26228</b>	
23 <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search report has been prepared by the EPO or JPO.....\$ 950.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33 (1)-(4) .....\$ 750.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$ 790.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....\$1,110.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 1,110.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 0.00	
Claims	Number Filed	Number Extra	Rate		
Total Claims	19 - 20 =	0	x \$18.00	\$ 0.00	
Independent Claims	2 - 3 =	0	x \$88.00	\$ 0.00	
Multiple Dependent Claim(s) (if applicable)				+ 300.00	\$ 0.00
TOTAL OF ABOVE CALCULATIONS =				\$ 1,110.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½ .				\$ 0.00	
SUBTOTAL =				\$ 1,110.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$ 0.00	
Extension of Time fee in the amount of \$				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 1,110.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 1,110.00	
				Amount to be refunded	\$
				Charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of <u>\$1,110.00</u> to cover the above fees is included. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. c. <input checked="" type="checkbox"/> The U.S. Patent and Trademark Office is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0089</u> . d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING: Information on this form may become public.</b> <b>Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038. e. <input checked="" type="checkbox"/> Charge any additional fee required under 37 C.F.R. 1.16 and 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136(a)(3)). <b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055 AT THE PRESENT ADDRESS OF:					
Bruce H. Bernstein GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clark Place Reston, VA 20191 (703) 716-1191					
 SIGNATURE <u>May 16, 2004</u> Bruce H. Bernstein NAME					
29.027 REGISTRATION NUMBER					

10/512090

DT15 Rec'd PCT/PTO 09 NOV 2004

P26228.P03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Hee-Yong LEE et al.  
Appl. No: : Not Yet Assigned (U.S. National Phase of PCT/KR03/00921) **PCT Branch**  
Filed : Concurrently Herewith (I.A. Filed May 9, 2003)  
For : SUBSTAINED RELEASE FORMULATION OF PROTEIN AND  
PREPARATION METHOD THEREOF

**CLAIM OF PRIORITY**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicant hereby claims the right of priority granted pursuant to 35 U.S.C. 119 and 365  
based upon Korean Application No. 10-2002-0025522, filed May 9, 2002. The International Bureau  
already should have sent a certified copy of the Korean application to the United Stated designated  
office. If the certified copy has not arrived, please contact the undersigned.

Respectfully submitted,  
Hee-Yong LEE et al.

*Bruce H. Bernstein Reg. No. 33,329*  
Bruce H. Bernstein  
Reg. No. 29,027

November 9, 2004  
GREENBLUM & BERNSTEIN, P.L.C.  
1950 Roland Clarke Place  
Reston, VA 20191  
(703) 716-1191